Capsule technology company BioProgress has reported its first set
of interim results since becoming an AIM-listed company, as well as
a distribution deal with Hoefliger.
DSM Biologics has dissolved its relationship with Qiagen and
Valentis regarding the pAlliance, a consortium supplying
ultra-pure, stable DNA plasmids and formulated DNA
Speciality chemical company Rohm and Haas has created a new
business unit, Advanced Biosciences, that specialises in the
production and purification of biopharmaceuticals. The new unit is
well placed to address the shortfall in production...
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
US Neuro Bioscience has signed an agreement to acquire a minimum of
75 per cent of the issued and outstanding share capital of CLL
Pharma, a French company engaged in the business of reformulating
drugs using its proprietary drug...
The European Federation of Biotechnology (EFB) is setting up a
trade office in Aarhus, Denmark for its activities in innovation
and functional genomics, reports Biotech Denmark on its website.
Two British firms, De Novo Pharmaceuticals and Peakdale Molecular,
are to enter into a joint collaboration to exploit their respective
skills in molecular design and chemistry synthesis, writes market
analysts Datamonitor this week.
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...
UK Science Minister Lord Sainsbury this week announced a new
initiative to develop 'a strategic approach' to the future of the
bioscience industry in the UK and to encourage growth in the
sector.
Nabi Biopharmaceuticals saw biopharmaceutical product sales -
driven by strong growth in sales of Nabi-HB - reaching record
levels of $89.5 million (€83m) in 2002, a 22 per cent increase from
2001 levels.
